Crosstalk between regulated cell death and immunity in redox dyshomeostasis for pancreatic cancer.

[1]  V. Sarafian,et al.  Redox regulation of the immune response , 2022, Cellular & Molecular Immunology.

[2]  Qin Dang,et al.  Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy , 2022, Theranostics.

[3]  Shuijun Zhang,et al.  CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma , 2022, Frontiers in Immunology.

[4]  Juan L. Vivero-Escoto,et al.  Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. , 2022, Advanced drug delivery reviews.

[5]  L. Wood,et al.  Pancreatic Cancer: Pathogenesis, Screening, Diagnosis and Treatment. , 2022, Gastroenterology.

[6]  Jun Yu Li,et al.  Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: Implications for risk stratification and frontline therapies in pancreatic cancer , 2022, Computational and structural biotechnology journal.

[7]  C. Doglioni,et al.  Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies , 2022, Science Translational Medicine.

[8]  Jihong Liu,et al.  Exploration of Redox-Related Molecular Patterns and the Redox Score for Prostate Cancer , 2021, Oxidative medicine and cellular longevity.

[9]  Xinwei Han,et al.  Derivation and Clinical Validation of a Redox-Driven Prognostic Signature for Colorectal Cancer , 2021, Frontiers in Oncology.

[10]  G. Kroemer,et al.  Cell death in pancreatic cancer: from pathogenesis to therapy , 2021, Nature Reviews Gastroenterology & Hepatology.

[11]  K. Takada,et al.  Reactive oxygen species in cancer: Current findings and future directions , 2021, Cancer science.

[12]  Xiaofeng Dai,et al.  Programmed cell death, redox imbalance, and cancer therapeutics , 2021, Apoptosis.

[13]  Xinwei Han,et al.  Comprehensive Molecular Analyses of a Novel Mutational Signature Classification System with Regard to Prognosis, Genomic Alterations, and Immune Landscape in Glioma , 2021, Frontiers in Molecular Biosciences.

[14]  Hai-long Piao,et al.  The double-edged roles of ROS in cancer prevention and therapy , 2021, Theranostics.

[15]  A. Carrier,et al.  Targeting Redox Metabolism in Pancreatic Cancer , 2021, International journal of molecular sciences.

[16]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[17]  M. Kopf,et al.  Redox regulation of immunometabolism , 2020, Nature Reviews Immunology.

[18]  J. Valle,et al.  Pancreatic cancer , 2020, The Lancet.

[19]  V. Bhardwaj,et al.  Reactive Oxygen Species, Metabolic Plasticity, and Drug Resistance in Cancer , 2020, International journal of molecular sciences.

[20]  Stephen A. Sastra,et al.  Cysteine depletion induces pancreatic tumor ferroptosis in mice , 2020, Science.

[21]  M. Karamouzis,et al.  Immunotherapy for pancreatic cancer: A 2020 update. , 2020, Cancer treatment reviews.

[22]  Shixiang Wang,et al.  Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction , 2019, eLife.

[23]  T. Creasy,et al.  The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort , 2019, Journal of Translational Medicine.

[24]  Z. Peng,et al.  Reactive Oxygen Species-Induced Lipid Peroxidation in Apoptosis, Autophagy, and Ferroptosis , 2019, Oxidative medicine and cellular longevity.

[25]  E. Collisson,et al.  Molecular subtypes of pancreatic cancer , 2019, Nature Reviews Gastroenterology & Hepatology.

[26]  F. Marincola,et al.  Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA) , 2018, Journal of Immunotherapy for Cancer.

[27]  J. Kleeff,et al.  Therapeutic developments in pancreatic cancer: current and future perspectives , 2018, Nature Reviews Gastroenterology & Hepatology.

[28]  H. Forman,et al.  Redox control of cancer cell destruction , 2018, Redox biology.

[29]  J. Liu,et al.  Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor , 2017, Nature Immunology.

[30]  T. Cotter,et al.  ROS signalling in the biology of cancer. , 2017, Seminars in cell & developmental biology.

[31]  S. Prasad,et al.  Reactive oxygen species (ROS) and cancer: Role of antioxidative nutraceuticals. , 2017, Cancer letters.

[32]  Shiyong Wu,et al.  Reactive oxygen species in redox cancer therapy. , 2015, Cancer letters.

[33]  Juan R. Cubillos-Ruiz,et al.  ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis , 2015, Cell.

[34]  Lucas B. Sullivan,et al.  Mitochondrial reactive oxygen species and cancer , 2014, Cancer & Metabolism.

[35]  J. Gostner,et al.  Redox regulation of the immune response , 2013, Redox report : communications in free radical research.

[36]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[37]  Yujin Hoshida,et al.  Nearest Template Prediction: A Single-Sample-Based Flexible Class Prediction with Confidence Assessment , 2010, PloS one.

[38]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[39]  S. Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[40]  Jill P. Mesirov,et al.  Subclass Mapping: Identifying Common Subtypes in Independent Disease Data Sets , 2007, PloS one.

[41]  Xavier Renaudin.  Reactive oxygen species and DNA damage response in cancer. , 2021, International review of cell and molecular biology.

[42]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.